APP and Alzheimer disease: In transgenic AD mice expressing human APP containing the human wt β-secretase site, which is what most AD patients have, deleting the cathepsin B gene improves memory deficits and reduces the brain amyloid plaque, which is a neuropathological hallmark of AD, that develop in these animals (140, 141).